Literature DB >> 31615499

Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis.

Mitsuro Kanda1, Masahiko Koike2, Chie Tanaka2, Daisuke Kobayashi2, Masamichi Hayashi2, Suguru Yamada2, Goro Nakayama2, Kenji Omae3, Yasuhiro Kodera2.   

Abstract

BACKGROUND: The global increase in elderly populations is accompanied by an increasing number of candidates for esophagectomy. Here we aimed to determine the postoperative outcomes after subtotal esophagectomy in elderly patients with esophageal cancer.
METHODS: Patients (n = 432) with who underwent curative-intent transthoracic subtotal esophagectomy with 2- or 3-field lymphadenectomies for thoracic esophageal cancer were classified as follows: non-elderly (age < 75 years, n = 373) and elderly (age ≥ 75 years, n = 59) and groups. To balance the essential variables including neoadjuvant treatment and stage of progression, we conducted propensity score analysis, and clinical characteristics, perioperative course and prognosis were compared.
RESULTS: After two-to-one propensity score matching, 100 and 50 patients were classified in the non-elderly and elderly groups. The elderly group had more comorbidities and lower preoperative cholinesterase activities and prognostic nutrition indexes. Although incidences of postoperative pneumonia, arrhythmia and delirium were slightly increased in the elderly group, no significant differences were observed in overall incidence of postoperative complications, rates of repeat surgery and death caused by surgery, and length of postoperative hospital stay between the two groups. There were no significant differences in disease-free and disease-specific survival as well as overall survival between the two groups.
CONCLUSION: Older age (≥75 years) had limited impact on morbidity, disease recurrence, and survival after subtotal esophagectomy. Therefore, age should not prevent older patients from benefitting from surgery.

Entities:  

Keywords:  Elderly; Esophageal cancer; Prognosis; Safety; Subtotal esophagectomy

Mesh:

Year:  2019        PMID: 31615499      PMCID: PMC6792188          DOI: 10.1186/s12893-019-0617-2

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.102


Background

Esophageal cancer is the sixth on the list of cancers with the highest mortality rates [1]. Moreover, the increasing general life expectancy leads to a larger number of elderly patients diagnosed as esophageal cancer [2]. Although esophagectomy is still positioned as the cornerstone treatment for esophageal cancer, it is associated with high morbidity and mortality rates for elderly patients despite recent advances in the surgical practice [1, 3, 4]. Moreover, there is controversy about whether long-term outcomes after esophagectomy in elderly patients are worse compared to those in younger patients [5, 6]. Physiological changes with advancing age lead to a decline in physiological reserve that potentially places elderly patients at greater risks of adverse events during early postoperative courses after esophagectomy [7]. Moreover, particularly in elderly patients, dysfunction of vital organs such as the heart, lungs or kidneys is associated frequently with esophageal cancer [6, 8]. Surgeons are typically more reluctant to perform esophagectomy for elderly patients due to the aggressiveness of surgery and high incidence of organ insufficiency. Therefore, we aimed to compare perioperative characteristics and prognosis of elderly patients with esophageal cancer to those of non-elderly patients.

Methods

Ethics approval and consent to participate

All procedures performed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was approved by the Institutional Review Board of Nagoya University (approval number 2017–0475) and written informed consent for surgery and usage of clinical data was obtained from all participants.

Selection of patients

The study flow-chart is shown in Fig. 1. Consecutive patients (n = 553) underwent esophagectomy for esophageal cancer at the Nagoya University Hospital (Department of Gastroenterological Surgery) between February 2005 and March 2017. We retrieved data for 432 patients in accordance with the criteria as follows: subtotal esophagectomy with systematic 2- or 3-field lymphadenectomy; clinical T1–3 esophageal cancer according to the Union for International Cancer Control (UICC) Classification (8th Edition); and R0 resection [9]. Patients who underwent planned two-stage surgery were excluded. Patients were classified into the non-elderly (age < 75 years, n = 373) or elderly (age ≥ 75 years, n = 59) groups. We used the propensity score matching to balance in essential variables for the comparison analyses that followed. Propensity scores were estimated using a logistic regression model based on sex, neoadjuvant treatment, operative approaches (open or thoracoscopic surgery), number of field dissected, tumor size, pathological T factor, N factor and tumor nodes metastasis (TNM) stage. Two-to-one matching without replacement was performed, and the resulting score-matched pairs were used in subsequent analyses.
Fig. 1

Study design

Study design

Patient management

The medical team cooperatively managed patients’ physical condition and comorbidities before surgery. No preoperative intervention (e.g. nutritional support and rehabilitation) was routinely provided specifically for elderly patients. All patients underwent subtotal esophagectomy with systematic 2- or 3-field lymphadenectomy. This procedure comprised subtotal esophageal resection through a right thoracotomy or thoracoscopic approaches and a 2- or 3-field lymphadenectomy of nodes at the cervical, mediastinal and intra-abdominal area [10]. The reconstruction method and route were determined according to the patient’s condition and the surgeon’s discretion. Based on evidence from the JCOG9907 study, neoadjuvant treatment is performed in patients with clinical stage II-IV esophageal cancer [11]. We consider postoperative adjuvant chemotherapy (mainly fluorouracil plus cisplatin) for patients who met following criteria; i) pathological stage II-IV, ii) no neoadjuvant treatment, iii) tolerability of chemotherapy and iv) patient consent. A routine postoperative follow-up screening including a physical, analyses of blood chemistry and tumor markers (squamous cell carcinoma [SCC] antigen and carcinoembryonic antigen) was provided every 3 months for the first and second year and every six months thereafter. Enhanced computed tomography (chest and abdominal cavity) once every 6 months and yearly thereafter. If the patient had a specific symptom, examinations were conducted sooner as needed.

Comparisons between groups

Preoperative background data included demographics, performance status by the Eastern Cooperative Oncology Group classification, comorbidities, physical condition, blood test results, prognostic nutritional index (PNI = 10 × serum albumin [g/dl] + 0.005 × total lymphocyte count [/mm3]), and Controlling Nutritional Status (CONUT) score [12, 13]. The TNM Classification of Malignant Tumors, 8th Edition was used to determine pathological stage [9]. A postoperative short-term outcome was evaluated based on 90-day postoperative mortality, a morbidity rate, and duration of postoperative hospitalization. We employed the Clavien-Dindo classification as a comprehensive evaluation method for postoperative complications [14]. To compare long-term outcomes, disease-free and disease-specific survival as well as overall survival were analyzed.

Statistical analysis

To compare the two groups, we used a qualitative χ2 and quantitative Mann–Whitney’s test. Survival curves were drawn using the Kaplan–Meier method. Survival differences were assessed using the Cox proportional hazards model. For all statistical analysis, JMP 13 software (SAS Institute Inc., NC, USA) was used. P < 0.05 represents a statistically significant difference.

Results

Patients’ backgrounds

Age distribution of the 432 patients was presented in Fig. 2a. The mean age was 65.8 ± 8.3 (standard deviation, SD) years, and the female:male ratio was 5.4:1. The median follow-up duration was 45.3 months. Before propensity score matching, 373 and 59 patients were classified in the non-elderly and elderly groups, respectively. As shown in Table 1, there were significant differences between the non-elderly and elderly groups in neoadjuvant treatment, number of field dissected, tumor size and pathological TNM stage. After two-to-one propensity score matching, 100 and 50 patients were classified in the non-elderly and elderly groups. Neoadjuvant treatment, number of field dissected, tumor size and pathological TNM stage were balanced by propensity score matching (Table 1).
Fig. 2

(a) Age distribution of patients who underwent subtotal esophagectomy. (b) Incidence of postoperative complications according to age

Table 1

Patient characteristics before and after propensity score matching

CharacteristicUnmatched comparisonMatched comparison
Non-elderly group (n = 373)Elderly group (n = 59)Standardized differenceNon-elderly group (n = 100)Elderly group (n = 50)Standardized difference
Sex (male/female)314 / 5959 / 90.01684 / 1642 / 80.000
Neoadjuvant treatment
 Not performed149 (40%)34 (58%)0.35953 (53%)29 (58%)0.101
 Performed224 (60%)25 (42%)47 (47%)21 (42%)
Surgical approach
 Open346 (93%)52 (88%)0.15889 (89%)45 (90%)0.033
 Thoracoscopic27 (7%)7 (12%)11 (11%)5 (10%)
Number of field dissected
 2-field dissection221 (59%)49 (83%)0.52878 (78%)40 (80%)0.049
 3-field dissection152 (41%)10 (17%)22 (22%)10 (20%)
Tumor size (mm), mean ± SD35.4 ± 21.645.2 ± 23.6− 0.43238.3 ± 21.044.1 ± 21.6−0.212
T factor
 pT0/pTis25 (7%)2 (3%)0.3511 (1%)00.159
 pT1157 (42%)29 (49%)51 (51%)27 (54%)
 pT254 (14%)7 (12%)11 (11%)6 (12%)
 pT3129 (35%)21 (36%)37 (37%)17 (34%)
 pT48 (2%)000
N factor
 pN0172 (46%)30 (51%)0.24245 (45%)25 (50%)0.183
 pN1102 (27%)17 (29%)30 (30%)15 (30%)
 pN265 (18%)10 (17%)20 (20%)9 (18%)
 pN334 (9%)2 (3%)5 (5%)1 (2%)
TNM stage
 017 (4%)2 (3%)0.5561 (1%)00.3000
 I97 (26%)23 (39%)36 (36%)21 (42%)
 II108 (29%)10 (17%)20 (20%)9 (18%)
 III103 (28%)22 (38%)36 (36%)19 (38%)
 IV48 (13%)2 (3%)7 (7%)1 (2%)

SD, standard deviation

(a) Age distribution of patients who underwent subtotal esophagectomy. (b) Incidence of postoperative complications according to age Patient characteristics before and after propensity score matching SD, standard deviation The elderly group was more likely to have significantly more overall comorbidities and cardiovascular disease (Table 2). The preoperative levels of serum cholinesterase were significantly lower in the elderly group (Table 2). The elderly group had significantly lower preoperative PNI values. No significant differences were found between CONUT scores (Table 2).
Table 2

Patients’ demographics and preoperative clinical characteristics

CharacteristicNon-elderly group (n = 100)Elderly group(n = 50) P
Age (years), mean ± SD65.0 ± 6.977.2 ± 2.1< 0.001
Sex (male/female)84 / 1642 / 81.000
Performance status (0/1)99 / 150 / 00.367
Comorbidity (%)
 Anya28 (28%)23 (46%)0.030
 Cardiovascular diseasea10 (10%)12 (24%)0.026
 Respiratory disease3 (3%)4 (8%)0.186
 Cerebrovascular disease7 (7%)4 (8%)0.823
 Renal dysfunction1 (1%)2 (4%)0.234
 Diabetes mellitus11 (11%)8 (16%)0.393
History of cancer (%)16 (16%)7 (14%)0.747
Brinkman index ≥1000 (%)31 (31%)17 (34%)0.711
Excessive alcohol consumption57 (57%)26 (52%)0.562
Body mass index, mean ± SD21.0 ± 3.121.1 ± 2.80.721
Blood test, median (range)
 Total lymphocyte count (/mm3)1600 (500–3400)1450 (500–2900)0.071
 Albumin (g/dl)4.1 (3.0–5.0)3.9 (2.9–4.9)0.092
 Cholinesterase (IU/l)276 (117–462)248 (96–369)0.015
 Cholesterol (mg/dl)188 (101–360)184 (118–261)0.579
 Creatinine (mg/dl)0.8 (0.2–1.6)0.9 (0.5–1.6)0.077
 CEA (ng/ml)2.5 (0.4–9.5)2.5 (0.9–20.1)0.987
 SCC (ng/ml)1.2 (0.3–7.9)1.3 (0.5–5.4)0.371
PNI, median (range)49.5 (34.5–60.0)46.3 (35.0–57.5)0.019
CONUT score, median (range)1 (0–5)1 (0–5)0.733
Neoadjuvant treatment (%)47 (47%)21 (42%)0.562

SD standard deviation, CEA carcinoembryonic antigen, SCC squamous cell carcinoma antigen, PNI prognostic nutritional index, CONUT Controlling Nutritional Status. aHypertension is not included

Patients’ demographics and preoperative clinical characteristics SD standard deviation, CEA carcinoembryonic antigen, SCC squamous cell carcinoma antigen, PNI prognostic nutritional index, CONUT Controlling Nutritional Status. aHypertension is not included

Intraoperative findings and pathological data

The data described in this section are shown in Table 3. Surgical procedure was evenly balanced by the propensity score matching between the two groups. SCC was a dominant histopathologic type and accounted for 94 and 98% of patients in the non-elderly and elderly groups. The elderly group had marginally greater amount of intraoperative blood loss and larger frequency of intraoperative transfusion, but smaller number of dissected lymph nodes, though there were no statistically significant differences.
Table 3

Intraoperative and pathological characteristics

CharacteristicNon-elderly group (n = 100)Elderly group(n = 50) P
Surgical approach
 Open89 (89%)45 (90%)0.851
 Thoracoscopic11 (11%)5 (10%)
Number of field dissected
 2-field dissection78 (78%)40 (80%)0.777
 3-field dissection22 (22%)10 (20%)
Reconstruction
 Jejunal flap22 (22%)10 (20%)0.777
 Gastric tube78 (78%)40 (80%)
Operative time (minutes), mean ± SD473 ± 111475 ± 1220.889
Intraoperative blood loss (ml), median (range)439 (31–1959)517 (187–1886)0.051
Intraoperative transfusion (%)13 (13%)13 (26%)0.053
Number of dissected lymph nodes mean ± SD43.7 ± 14.840.1 ± 15.80.097
Histopathologic Type (%)
 Squamous cell carcinoma94490.192
 Adenocarcinoma21
 Others40
Tumor size (mm), mean ± SD38.3 ± 21.044.1 ± 21.60.141
Multiple lesion (%)15 (15%)8 (16%)0.873
T factor
 pT0/pTis1 (1%)00.806
 pT151 (51%)27 (54%)
 pT211 (11%)6 (12%)
 pT337 (37%)17 (34%)
 pT400
N factor
 pN045 (45%)25 (50%)0.779
 pN130 (30%)15 (30%)
 pN220 (20%)9 (18%)
 pN35 (5%)1 (2%)
TNM stage
 01 (1%)00.546
 I36 (36%)21 (42%)
 II20 (20%)9 (18%)
 III36 (36%)19 (38%)
 IV7 (7%)1 (2%)

SD, standard deviation

Intraoperative and pathological characteristics SD, standard deviation

Postoperative short-term outcomes

Postoperative complications of at least grade 2 were experienced by 36 (36%) and 22 (44%) patients in the non-elderly and elderly groups (Table 4). Moreover, 12 (12%) and 4 (8%) patients in the non-elderly and elderly groups experienced postoperative complications of at least grade 3 according to the Clavien-Dindo classification. Although incidences of postoperative pneumonia, arrhythmia and delirium were slightly increased in the elderly group (Fig. 2b), there were no significant differences in overall incidence of postoperative complications (at least grade 2), rates of repeat surgery and operative death between the two groups (Table 4). The mean lengths of postoperative hospitalizations were similar between groups. The elderly group was less likely to receive postoperative adjuvant treatment (Table 4).
Table 4

Postoperative course

CharacteristicNon-elderly group (n = 100)Elderly group (n = 50) P
Postoperative complications (%)
 CD grade 2 or more36 (36%)22 (44%)0.345
 CD grade 3 or more12 (12%)4 (8%)0.445
Reoperation (%)6 (6%)2 (4%)0.599
Operative deatha (%)01 (2%)0.137
Length of postoperative stay (days), mean ± SD28.1 ± 20.526.0 ± 20.00.395
Postoperative adjuvant therapy (%)12 (12%)1 (2%)0.022

CD Clavien-Dindo classification, SD standard deviation. aDeath within 90 days after surgery

Postoperative course CD Clavien-Dindo classification, SD standard deviation. aDeath within 90 days after surgery

Long-term outcomes

No significant differences were observed in the curves for disease-free and disease-specific survival of the two groups (Fig. 3 a and b). Moreover, overall survival rates were comparable between the two groups (Fig. 3c).
Fig. 3

Prognosis of patients who underwent a curative resection for esophageal cancer according to age. (a) Disease-free, (b) disease-specific and (c) overall survival

Prognosis of patients who underwent a curative resection for esophageal cancer according to age. (a) Disease-free, (b) disease-specific and (c) overall survival

Discussion

Here we sought to determine the outcomes of elderly patients with esophageal cancer after subtotal esophagectomy for. After adjustment by propensity score matching, we found that no significant differences were observed in overall incidence of postoperative complications, the rates of repeat surgery and death during surgery, length of postoperative hospitalization, and prognosis between the non-elderly and elderly patients. Aging is a poor descriptor of physical, mental, or medical functional condition [15, 16]. Accordingly, selecting appropriate treatment in elderly patients with esophageal cancer is always challenging because impaired functional and nutritional status, comorbidities, cognitive function, quality of life after surgery, and life expectancy should be concerned [17, 18]. From lack of an established definition, the definitions of elderly are arbitrary and differ among studies (e.g., > 65, > 70, or > 80 years). Here we defined 75 years as “elderly,” because it is considered as the late-stage of elderly by Japanese society. Our comparison here of the elderly and non-elderly groups reveal that the rate of repeat surgery, mortality and length of postoperative hospitalization, despite a slightly higher incidence of pneumonia, arrhythmia and delirium, and more frequent disadvantages including overall comorbidity, cardiovascular disease as well as impaired immune-nutritional status in the former group. These findings indicate that subtotal esophagectomy is feasible for selected elderly patients when the medical team provides an appropriate perioperative care. The possible explanations of acceptable outcomes of elderly patients are as follows: 1) The multidisciplinary medical team comprised surgeons, anesthesiologists, geriatrics physicians, physical therapist, and a nutritionist who supported patients. 2) Patients at high risk of adverse cardiopulmonary events underwent planned two-stage surgery or were subjected to different treatment. 3) Patientspostoperative complications were intensively managed to prevent exacerbation of their disease. Despite acceptable short-term outcomes, the length of hospital stay was long (mean, 28.1 and 26.0 days in the non-elderly and elderly groups). In Japan, the length of hospital stay tends to be much longer than that in the Western countries because of the difference in social and medical systems [2, 5, 7, 8, 19]. Patients typically return home to daily life directly after discharge so that they stay at the hospital until they get substantial recovery, fair oral intake, and removal of all drainage tubes. Correlations between age and prognosis of patients with esophageal cancer is a subject of debate. Diversity in definitions of elderly patients, the inclusion criteria, methods of analysis likely contribute to the discrepancy [7, 8, 18–20]. In the present study, long-term outcomes in the elderly group was comparable to those of the non-elderly group after adjustment of essential variables including neoadjuvant treatment, number of field dissected, tumor size and TNM stage with the propensity score matching. Further prospective studies addressing survival, cost-effectiveness, and postoperative quality of life will be required to establish treatment guidelines for elderly esophageal cancer patients. This present study has limitations, such as a limited number of patients and potential selection biases due to the retrospective nature even after propensity score matching. In the present study, only patients who underwent subtotal esophagectomy were analyzed. Frail patients who had severe comorbidities or poor performance status were considered to be unfit for esophagectomy and subjected to different treatments. The lack of objective assessment criteria for postoperative quality of life prevented us from deepening the discussion. Unfortunately, survival data of patients undergoing palliative care that possibly support our conclusion are unavailable this time.

Conclusion

Short-term and long-term outcomes after subtotal esophagectomy were comparable between the elderly and non-elderly patients. Our findings indicate that subtotal esophagectomy is justified for selected elderly esophageal cancer patients and should not be withheld because of a patients’ age.
  20 in total

1.  Outcome of elderly patients with oesophageal squamous cell carcinoma after surgery.

Authors:  H-X Yang; L Ling; X Zhang; P Lin; T-H Rong; J-H Fu
Journal:  Br J Surg       Date:  2010-06       Impact factor: 6.939

2.  The Controlling Nutritional Status Score Serves as a Predictor of Short- and Long-Term Outcomes for Patients with Stage 2 or 3 Gastric Cancer: Analysis of a Multi-institutional Data Set.

Authors:  Song Ryo; Mitsuro Kanda; Seiji Ito; Yoshinari Mochizuki; Hitoshi Teramoto; Kiyoshi Ishigure; Toshifumi Murai; Takahiro Asada; Akiharu Ishiyama; Hidenobu Matsushita; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Kenta Murotani; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2018-12-18       Impact factor: 5.344

3.  Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for esophageal squamous cell carcinoma underwent radical surgery.

Authors:  D Zhang; Y Zheng; Z Wang; Q Huang; X Cao; F Wang; S Liu
Journal:  Eur J Surg Oncol       Date:  2017-06-23       Impact factor: 4.424

4.  Risk Prediction of Postoperative Pneumonia After Subtotal Esophagectomy Based on Preoperative Serum Cholinesterase Concentrations.

Authors:  Mitsuro Kanda; Masahiko Koike; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Suguru Yamada; Kenji Omae; Yasuhiro Kodera
Journal:  Ann Surg Oncol       Date:  2019-06-13       Impact factor: 5.344

5.  Outcome of esophagectomy for cancer in elderly patients.

Authors:  Tanja M Cijs; Cees Verhoef; Ewout W Steyerberg; Linetta B Koppert; T C Khe Tran; Bas P L Wijnhoven; Hugo W Tilanus; Jeroen de Jonge
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

6.  Esophagectomy for cancer in octogenarians: should we do it?

Authors:  Elizabeth Paulus; Caroline Ripat; Vadim Koshenkov; Angela T Prescott; Kiran Sethi; Heather Stuart; Gregory Tiesi; Alan S Livingstone; Danny Yakoub
Journal:  Langenbecks Arch Surg       Date:  2017-03-16       Impact factor: 3.445

Review 7.  Oesophageal cancer.

Authors:  Jesper Lagergren; Elizabeth Smyth; David Cunningham; Pernilla Lagergren
Journal:  Lancet       Date:  2017-06-22       Impact factor: 79.321

8.  Extended esophagectomy in elderly patients with esophageal cancer: minor effect of age alone in determining the postoperative course and survival.

Authors:  B B Pultrum; D J Bosch; M W N Nijsten; M G G Rodgers; H Groen; J P J Slaets; J Th M Plukker
Journal:  Ann Surg Oncol       Date:  2010-02-24       Impact factor: 5.344

9.  Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly.

Authors:  Julian A Abrams; Donna L Buono; Joshua Strauss; Russell B McBride; Dawn L Hershman; Alfred I Neugut
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

10.  Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer.

Authors:  Mitsuro Kanda; Akira Mizuno; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Naoki Iwata; Masamichi Hayashi; Suguru Yamada; Goro Nakayama; Tsutomu Fujii; Hiroyuki Sugimoto; Masahiko Koike; Hideki Takami; Yukiko Niwa; Kenta Murotani; Yasuhiro Kodera
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more
  8 in total

1.  Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus.

Authors:  Dai Shimizu; Masahiko Koike; Mitsuro Kanda; Fuminori Sonohara; Norifumi Hattori; Masamichi Hayashi; Chie Tanaka; Suguru Yamada; Yasuhiro Kodera
Journal:  Surg Today       Date:  2020-07-07       Impact factor: 2.549

2.  Long-term Outcomes Following Esophagectomy in Older and Younger Adults with Esophageal Cancer.

Authors:  Aaron R Dezube; Lisa Cooper; Emanuele Mazzola; Daniel P Dolan; Daniel N Lee; Suden Kucukak; Luis E De Leon; Clark Dumontier; Bayonle Ademola; Emily Polhemus; Raphael Bueno; Abby White; Scott J Swanson; Michael T Jaklitsch; Laura Frain; Jon O Wee
Journal:  J Gastrointest Surg       Date:  2022-03-31       Impact factor: 3.267

Review 3.  Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes; A Systematic Review and Pooled Analysis.

Authors:  Styliani Mantziari; Hugo Teixeira Farinha; Vianney Bouygues; Jean-Charles Vignal; Yannick Deswysen; Nicolas Demartines; Markus Schäfer; Guillaume Piessen
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

4.  Impact of frailty on the long-term outcomes of elderly patients with esophageal squamous cell carcinoma.

Authors:  Tsuyoshi Tanaka; Koichi Suda; Masaki Ueno; Toshiro Iizuka; Ichiro Uyama; Harushi Udagawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2022-03-25

5.  Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer.

Authors:  Lisa Cooper; Aaron R Dezube; Luis E De León; Suden Kucukak; Emanuele Mazzola; Clark Dumontier; Harvey Mamon; Peter Enzinger; Michael T Jaklitsch; Laura N Frain; Jon O Wee
Journal:  Eur J Surg Oncol       Date:  2021-04-17       Impact factor: 4.037

6.  Outcomes of curative esophageal cancer surgery in elderly: A meta-analysis.

Authors:  Nikolaj S Baranov; Cettela Slootmans; Frans van Workum; Bastiaan R Klarenbeek; Yvonne Schoon; Camiel Rosman
Journal:  World J Gastrointest Oncol       Date:  2021-02-15

Review 7.  Management of elderly patients with esophageal squamous cell cancer.

Authors:  Yasuo Hamamoto; Kentaro Murakami; Ken Kato; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2022-08-05       Impact factor: 2.925

8.  Surveillance of Esophageal Cancer in the Republic of Uzbekistan from 2000 to 2018.

Authors:  Abror Yusupbekov; Mitsuro Kanda; Bekhzod Usmanov; Otabek Tuychiev; Sayfiddin Baymakov; Junichi Sakamoto; Akhrorbek Yusupbekov
Journal:  Asian Pac J Cancer Prev       Date:  2020-08-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.